Skip to main content
. 2018 Jan 31;89(7):710–716. doi: 10.1136/jnnp-2017-317219

Table 4.

Mean±SD scores of selected items of Unified Parkinson’s Disease Rating Scale (UPDRS-III), dyskinesia scores (UPDRS-IV) and levodopa-equivalent daily doses (LEDD), at baseline and at 6 months in medical group on-medication/off-medication, and in surgical group on-medication/off-medication on-stimulation/off-stimulation

Medical group Surgical group
Baseline 6 months Baseline 6 months
Off-medication On-medication Off-medication On-medication Off-medication On-medication Off-medication
off-stimulation
On-medication
off-stimulation
Off- medication
on-stimulation
On-medication
on-stimulation
Tremor (items 20–21) 8.3±6.4 2.1±3.9 6.9±5.6 2.7±4.7 5.1±3.4 2.3±4.2 6.1±4.6 2.1±4.2 0.4±0.5 0.4±0.8
Speech (item 18) 1.3±0.7 0.9±0.5 1.2±0.8 0.7±0.5 1.2±0.7 0.8±0.7 1.3±0.7 1±0.7 1.2±0.7 0.9±0.6
Akinesia (items 22–26) 15.8±5.6 9.1±5.1 14.4±4.4 7.9±5.4 14.3±6.6 10±6.1 15.7±6.3 9.1±3.3 9.7±5 10.1±6.6
Axial (items 27–31) 4.4±2.4 1.4±1.3 3.9±2.8 1.8±1.8 2.8±1.9 1.3±1 2.4±1.9 1.4±1.2 2.0±1.4 1.8±2.0
Dyskinesia 1.7±2.9 1.5±2.6 1.5±2.1 1.1±0.3
LEDD (mg) 1043±516 1180±548 1376±883* 1054±488*

Significant P values:

Medical group off-medication vs surgical group off-medication on-stimulation: tremor P=0.001; akinesia: P=0.015.

Surgical group off-medication scores at baseline vs off-medication on-stimulation scores at 6 months: tremor P=0.002; akinesia: P=0.026.

*One patient in surgical group had 8 mg of trihexyphenidyl, both at baseline and at 6 months follow-up.